Systematic Review on Edaravon Dexborneo Combined with Butylphthalide and Sodium Chloride in the Treatment of Acute Cerebral Infarction
OBJECTIVE:To systematically evaluate the efficacy and safety of edaravon dexborneo combined with butylphthalide and sodium chloride in the treatment of acute cerebral infarction.METHODS:PubMed,CBM,CNKI,Wanfang Data and VIP were retrieved to collect randomized controlled trial(RCT)of clinical efficacy and safety of edaravon dexborneo combined with butylphthalide and sodium chloride(observation group)compared with butylphthalein and sodium chloride alone(control group)in the treatment of acute cerebral infarction,the retrieval time was from database establishment to Sept.2023.After data extraction and quality evaluation,Meta-analysis was carried out by RevMan 5.3 statistical software.RESULTS:A total of 9 RCT including 995 patients were enrolled.Meta-analysis results showed that the total effective rate(RR=1.21,95%CI=1.14-1.29,P<0.000 01),cure rate(RR=1.41,95%CI=1.08-1.83,P=0.01)and markedly effective rate(RR=1.35,95%CI=1.14-1.61,P=0.000 5)in the observation group were higher than those in the control group,the National Institute of Health Stroke Scale score(MD=-3.08,95%CI=-4.23--1.92,P<0.000 01)and inefficiency rate(RR=0.31,95%CI=0.21-0.46,P<0.000 01)were significantly lower than those in the control group,with statistically significant differences.There were no significant differences in the modified Rankin scale score(MD=-0.47,95%CI=-0.97-0.03,P=0.06)and the incidence of adverse drug reactions(RR=0.74,95%CI=0.49-1.12,P=0.15)between two groups.CONCLUSIONS:The clinical efficacy of edaravon dexborneo combined with butylphthalein and sodium chloride in the treatment of acute cerebral infarction is better than that of butylphthalein and sodium chloride alone,and the safety is comparable.
Edaravon dexborneoButylphthalide and sodium chlorideAcute cerebral infarctionMeta-analysis
万方数据
维普
